Table 3 Percentages of patients with genotype included in quadrivalent and nonavalent vaccine.

From: Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations

Group

% patients with genotype included in quadrivalentvaccine

% patients with genotype included in nonavalent vaccine

Quadrivalent vs. nonavalent

p-value (p)

Group I

58% (80/138)

67.4% (93/138)

58% < 67.4%, p = 0.0002* (M)

Group II

50.4% (69/137)

70.1% (96/137)

50.4% < 70.1%, p < 0.0001* (M)

Group III

38.% (113/297)

59.6% (177/297)

38% < 59.6%, p < 0.0001* (M)

Statistical analysis among groups++

p = 0.0003* (C)

Group I**, p = 0.0153 (Z)

p = 0.068 (C)

 

Total group

45.8% (262/572)

64.3% (368/572)

45.8% < 64.3%, p < 0.0001* (M)

  1. *Significant test, **Most frequent, ***Less frequent; C = multiple comparison χ2 test; Z = Z-test; M = McNemar exact test; ++  = the statistical analysis was performed for column; p = p-value.
Back to article page